Delfi Diagnostics utilizes the DELFI method, which employs advanced machine learning and next-generation sequencing to analyze cell-free DNA fragments from non-invasive blood samples for early cancer detection. This approach enhances the identification of previously unrecognized cancer-associated DNA fragments, addressing the limitations of existing liquid biopsy methods that rely solely on known mutations.
Funding
$431.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing liquid biopsy methods for early cancer detection often rely on identifying known cancer-associated mutations, which limits their ability to detect a broader range of early-stage cancers. These methods may miss previously unrecognized cancer-associated DNA fragments, hindering early diagnosis and treatment.
Solution
Delfi Diagnostics utilizes the DELFI (DNA Evaluation of Fragments for early Interception) method, a novel approach that analyzes cell-free DNA fragments in blood samples using advanced machine learning and next-generation sequencing. By examining millions of data points, the DELFI method identifies previously unrecognized cancer-associated patterns in cell-free DNA fragmentation. This comprehensive analysis enhances the detection of early-stage cancers compared to methods focused solely on known mutations. The DELFI platform aims to provide a scalable and accessible solution for early cancer screening and treatment monitoring.
Target Audience
The primary target audience includes healthcare providers, health systems, and pharmaceutical companies seeking advanced solutions for early cancer detection, screening, and treatment monitoring.
Features
- Fragmentomics platform analyzing cell-free DNA fragmentation patterns
- Advanced machine learning algorithms to identify cancer-associated signatures
- Next-generation sequencing for high-throughput analysis of DNA fragments
- Non-invasive liquid biopsy approach using standard blood samples
- DELFI-TF Treatment Monitoring for research service and partnerships
- FirstLook Lung for early lung cancer detection